<!DOCTYPE html>
<html lang="en">
<head>
<title>Hepatitis C</title>
<meta http-equiv="Content-Type" content="text/html;charset=utf-8">
<link rel="stylesheet" type="text/css" href="../../../public/css/offline.css" />
<script src="../../../public/javascripts/jquery-1.10.2.min.js"></script>
</head>
<body class="dsg-wb">

<table width="80%" class="offline">
<tr>
  <td colspan="3" class="header"><h1><a href="/">JPAC</a> <span>Joint United Kingdom (UK) Blood Transfusion and Tissue Transplantation Services Professional Advisory Committee</span></h1></td>
</tr>
<tr class="tabs">
  <td colspan="3">
              <ul>
                  <li id="64df60ce-a8e2-4c07-8729-68f41eb42fc3" class="whole-blood-and-components"><a href="../../../dsg/wb/guidelines.html"  class="active">Whole Blood and Components</a></li>
                  <li id="ddb09bf2-3dc0-4eb2-ba57-a5db69331dd1" class="geographical-disease-risk-index"><a href="../../../dsg/gdri/guidelines.html" >Geographical Disease Risk Index</a></li>
                </ul>
        </td>
</tr>
<tr>
  <td class="spacerow" colspan="3"></td>
</tr>
<tr>
  <td class="sidebar" width="25%">
    <div class="well">
          <ul class="openContentSectionWithSubs sidebarTopHeader"><li id="64df60ce-a8e2-4c07-8729-68f41eb42fc3" class="whole-blood-and-components sectionHead first last"><a href="../../../dsg/wb.html">Whole Blood and Components</a>
<ul class="">
<li id="42be2de8-89aa-4908-8bc8-702f9e636a81" class="a-z-search active first"><a href="../../../dsg/wb/guidelines.html">A-Z Search</a>
</li><li id="1f7e1f13-8b29-4772-ae9d-2b5cc3d59491" class="updates"><a href="../../../dsg/wb/latest-updates.html">Updates</a>
</li><li id="f83d68fb-19de-4588-9a36-a8bba0aa6494" class="drug-index"><a href="../../../dsg/wb/drug-index.html">Drug Index</a>

</li><li id="769da873-1c35-4600-8be8-d2df902570a0" class="preliminaries"><a href="../../../dsg/wb/preliminaries.html">Preliminaries</a>
<ul class="">
<li id="258895c3-f3dd-45c6-932c-3fe4795870c2" class="introduction first"><a href="../../../dsg/wb/preliminaries/introduction.html">Introduction</a>
</li><li id="ef298454-8327-4f6c-9f4a-835e437df103" class="document-and-change-control"><a href="../../../dsg/wb/preliminaries/document-and-change-control.html">Document and Change Control</a>
</li><li id="093e6463-a089-49dd-9199-c8f92559f486" class="general-principles"><a href="../../../dsg/wb/preliminaries/general-principles.html">General Principles</a>
</li><li id="96f75c3a-2c62-445b-847c-353098eaec1e" class="medication"><a href="../../../dsg/wb/preliminaries/medication.html">Medication</a>
</li><li id="ed51942d-a7fd-42f7-8269-d23b879f99ca" class="inspection-of-the-donor"><a href="../../../dsg/wb/preliminaries/inspection-of-the-donor.html">Inspection of the Donor</a>
</li><li id="99af8b5e-491b-4d67-b69a-812d81af4d7d" class="use-of-alphabetical-listing last"><a href="../../../dsg/wb/preliminaries/use-of-alphabetical-listing.html">Use of Alphabetical Listing</a>
</li></ul>
</li><li id="753eb36f-2636-414c-84ee-1004e197502d" class="appendices"><a href="../../../dsg/wb/appendicies.html">Appendices</a>
<ul class="">
<li id="e147bd96-a025-4ffa-b530-b9abefc27043" class="appendix-1---estimated-blood-volume-for-female-donors-after-nadler--by-height-and-weight first"><a href="../../../dsg/wb/appendicies/appendix-1.html">Appendix 1 - Estimated Blood Volume for Female donors (after Nadler)  by height and weight</a>
</li><li id="2f1eca54-e34f-4ece-90a4-7dfe0f210c8d" class="appendix-2---table-of-immunisations-"><a href="../../../dsg/wb/appendicies/appendix-2-table-of-immunizations.html">Appendix 2 - Table of Immunisations </a>
</li><li id="a27f8ce9-b4f6-4a9b-baf0-6f655955a9aa" class="appendix-3---maximum-permitted-ecv-for-component-donors"><a href="../../../dsg/wb/appendicies/appendix-3-maximum-permitted-extra-corporeal-volume-for-component-donors.html">Appendix 3 - Maximum permitted ECV for component donors</a>
</li><li id="90c869cb-7256-4604-8699-d8a86f78aa26" class="appendix-4---management-of-post-donation-illness last"><a href="../../../dsg/wb/appendicies/appendix-4-management-of-post-donation-illness.html">Appendix 4 - Management of post donation illness</a>
</li></ul>
</li><li id="b62a2d12-6d94-4106-92a8-1de426a4b863" class="source-files last"><a href="../../../dsg/wb/source-files.html">Source Files</a>
</li></ul>
</li></ul>
    </div>
  </td>
  <td width="5%"></td>
  <td width="70%" class="content">
    <h2>Hepatitis C</h2>    

<table class="data-table"><tbody><tr><td class="data-sub" colspan="2"><table class="data-sub-table"><tbody><tr><td class="data-header" colspan="2">1. Person with current Hepatitis C infection</td></tr><tr class="data-row"><td class="data-label">Obligatory</td><td class="data-value"><p><b>Must not donate.</b></p></td></tr><tr class="data-row"><td class="data-label">See if Relevant</td><td class="data-value"><p><a href="../../../dsg/wb/guidelines/bl008-blood-safety-entry.html">Blood Safety Entry</a></p></td></tr><tr class="data-row"><td class="data-label">Additional Information</td><td class="data-value"><p>Hepatitis C&nbsp;Virus (HCV)&nbsp;is a serious infection that can lead to chronic liver disease, liver cancer (hepatoma) and chronic fatigue syndrome. It has also been linked with malignant lymphomas and autoimmune disease. The infection is very easily spread by transfusion.<br />
<br />
Individuals who are chronically infected are sometimes referred to as 'carriers'. They often have no, or minimal, symptoms associated with their infection.<br />
<br />
Many cases are linked to previous drug use and, before the introduction of HCV screening of blood donations, to transfusion.</p></td></tr><tr class="data-row"><td class="data-label">Reason for change</td><td class="data-value"><p>See below</p></td></tr></tbody></table></td></tr><tr><td class="data-sub" colspan="2"><table class="data-sub-table"><tbody><tr><td class="data-header" colspan="2">2. Person with treated Hepatitis C infection</td></tr><tr class="data-row"><td class="data-label">Includes</td><td class="data-value"><p>Individuals who have received successful treatment for HCV.</p></td></tr><tr class="data-row"><td class="data-label">Obligatory</td><td class="data-value"><p><b>Must not donate.</b></p></td></tr><tr class="data-row"><td class="data-label">Discretionary</td><td class="data-value"><p>If six months has elapsed from the completion of therapy and the individual has been told their treatment has cleared their HCV infection, accept.<br />
Samples should be taken to confirm that the donor is HCV antibody negative before a full donation is taken.</p></td></tr><tr class="data-row"><td class="data-label">See if Relevant</td><td class="data-value"><p><a href="../../../dsg/wb/guidelines/bl008-blood-safety-entry.html">Blood Safety Entry</a></p></td></tr><tr class="data-row"><td class="data-label">Additional Information</td><td class="data-value"><p>Individuals who have been successfully treated will usually remain HCV antibody positive for many years. As a negative HCV antibody screening test is required before blood can be issued, their blood cannot be used.</p></td></tr><tr class="data-row"><td class="data-label">Reason for change</td><td class="data-value"><p>See below</p></td></tr></tbody></table></td></tr><tr><td class="data-sub" colspan="2"><table class="data-sub-table"><tbody><tr><td class="data-header" colspan="2">3. Current or Former Sexual Partner of Affected Individual</td></tr><tr class="data-row"><td class="data-label">Obligatory</td><td class="data-value"><p><strong>Must not donate if</strong><br />
Less than three months from the last sexual contact.<br />
&nbsp;</p></td></tr><tr class="data-row"><td class="data-label">Discretionary</td><td class="data-value"><p>Donors who have a current sexual partner with a history of previous HCV infection may be able to donate, depending on the status of their partner:.</p>


<p>1. If the partner has been treated for HCV infection, and has been free of therapy for six months, and is in sustained remission, accept.</p>


<p>2. If the partner has evidence of previous HCV infection (HCV RNA negative, anti-HCV positive), and has been fully assessed by an appropriate clinician who has confirmed that there is no current HCV infection, accept.<br />
&nbsp;</p></td></tr><tr class="data-row"><td class="data-label">See if Relevant</td><td class="data-value"><p><a href="../../../dsg/wb/guidelines/bl008-blood-safety-entry.html">Blood Safety Leaflet&nbsp;</a></p></td></tr><tr class="data-row"><td class="data-label">Additional Information</td><td class="data-value"><p>Confirmation of the success of treatment of the HCV positive partner is not required.</p>


<p>Individuals who remain HCV RNA negative six months after completing treatment are likely to have been ‘cured’, with a risk of relapse of less than 1%</p>


<p>In the United Kingdom the risk of sexual transmission of HCV from an infected individual to a sexual partner is low, but not zero.</p>


<p>As the treated individual would have a very low (&lt;1%) risk of relapse of infection and sexual transmission of the hepatitis C virus is rare, the transmission of hepatitis C from a successfully treated individual to a sexual partner is most unlikely.</p>


<p>All donations in the UK undergo HCV NAT screening so that the chance of a window period donation escaping detection is also exceedingly low (estimated residual risk for HCV transmission from a UK blood donation for 2014-2016 is 1 in 95.8 million donations).</p>


<p>&nbsp;</p>


<p><b>Sexual Partners of anti-HCV positive, PCR negative donors</b><br />
Individuals who have cleared an acute HCV infection naturally are sometimes identified through HCV testing, including testing of a blood donation. Such individuals will be HCV RNA negative but HCV antibody positive. Unlike people who have been treated for HCV infection, they may not have received appropriate clinical follow up, including repeat HCV RNA testing several months after the original negative result. Unless the individual has undergone specialist assessment and been given the assurance that they are not currently infected, their partner is not eligible to donate.</p></td></tr><tr class="data-row"><td class="data-label">Reason for change</td><td class="data-value"><p>See below</p></td></tr></tbody></table></td></tr><tr><td class="data-sub" colspan="2"><table class="data-sub-table"><tbody><tr><td class="data-header" colspan="2">4. Person Currently or Formerly Sharing a Home with an Affected Individual</td></tr><tr class="data-row"><td class="data-label">Discretionary</td><td class="data-value"><p>Accept.</p></td></tr><tr class="data-row"><td class="data-label">See if Relevant</td><td class="data-value"><p>Current or Former Sexual Partner of Affected Individual, above. &nbsp;</p></td></tr><tr class="data-row"><td class="data-label">Additional Information</td><td class="data-value"><p>Hepatitis C is neither contagious nor spread by the faecal-oral route. It is usually only spread through a direct blood to blood route. For these reasons household contacts do not need to be deferred.</p></td></tr><tr class="data-row"><td class="data-label">Reason for change</td><td class="data-value"><p>See below</p></td></tr></tbody></table></td></tr><tr class="data-row"><td class="data-label">Reason for change</td><td class="data-value"><p>This entry was updated to remove the reference to a separate entry for Northern Ireland. This is to reflect changes in donor selection criteria for donors in Northern Ireland (1st June 2020) which are in line with the other UK Blood Services and the SaBTO Donor Selection Criteria Review Report (2017).</p></td></tr><tr class="data-row"><td class="data-label">Donor Information</td><td class="data-value"><p>If you wish to obtain more information regarding a personal medical issue please contact your <a href="../../../dsg/wb/guidelines/nn099-national-help-lines.html">National Help Line</a>.<br />
<br />
Please do not contact this web site for personal medical queries, as we are not in a position to provide individual answers.</p></td></tr></tbody></table>
<div class="pull-right attachments"><div class="cms images">
  
</div></div>

  
<dl class="update-information"><dt class="data-label"><h4>Update Information</h4></dt><dd class="data-value"><p>This entry was last updated in:<br />
DSG-WB Edition 203, Release 50</p></dd></dl>  </td>
</tr>
</table>
</body>
</html>